Literature DB >> 10498622

Presence of proteinase 3 in secretory vesicles: evidence of a novel, highly mobilizable intracellular pool distinct from azurophil granules.

V Witko-Sarsat1, E M Cramer, C Hieblot, J Guichard, P Nusbaum, S Lopez, P Lesavre, L Halbwachs-Mecarelli.   

Abstract

Proteinase 3 (PR3), which is also called myeloblastin, the target autoantigen for antineutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis, is a serine proteinase stored in azurophil granules of human neutrophils. We have previously shown that, in contrast to elastase or myeloperoxidase, PR3 is also expressed at the plasma membrane of a subset of unactivated neutrophils and that a high proportion of neutrophils expressing membrane PR3 is a risk factor for vasculitis. The present study demonstrates that the association of PR3 with the plasma membrane is not an ionic interaction and seems to be covalent. Fractionation of neutrophils shows that, besides the azurophil granules, PR3 could be detected both in specific granules and in the plasma membrane-enriched fraction containing secretory vesicles, whereas elastase and myeloperoxidase were exclusively located in azurophil granules. Electron microscopy confirms that PR3 is present along with CR1 in secretory vesicles as well as in some specific granules. In neutrophils stimulated with an increasing dose of FMLP, membrane PR3 expression increased with the degranulation of secretory vesicles, followed by specific granules, and culminated after azurophil granules mobilization. The presence of a readily plasma membrane-mobilizable pool of PR3 contained in the secretory vesicles might play a relevant role in the pathophysiological mechanisms of ANCA-associated vasculitis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10498622

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  37 in total

1.  The use of small molecule high-throughput screening to identify inhibitors of the proteinase 3-NB1 interaction.

Authors:  M Choi; C Eulenberg; S Rolle; J P von Kries; F C Luft; R Kettritz
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

Review 2.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

3.  Increased neutrophil membrane expression and plasma level of proteinase 3 in systemic vasculitis are not a consequence of the - 564 A/G promotor polymorphism.

Authors:  M Abdgawad; T Hellmark; L Gunnarsson; K W A Westman; M Segelmark
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

4.  Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB.

Authors:  Seok-Yong Eum; Ji-Hye Kong; Min-Sun Hong; Ye-Jin Lee; Jin-Hee Kim; Soo-Hee Hwang; Sang-Nae Cho; Laura E Via; Clifton E Barry
Journal:  Chest       Date:  2009-09-11       Impact factor: 9.410

Review 5.  How anti-neutrophil cytoplasmic autoantibodies activate neutrophils.

Authors:  R Kettritz
Journal:  Clin Exp Immunol       Date:  2012-09       Impact factor: 4.330

Review 6.  Neutrophil proteinase 3 and dipeptidyl peptidase I (cathepsin C) as pharmacological targets in granulomatosis with polyangiitis (Wegener granulomatosis).

Authors:  Brice Korkmaz; Adam Lesner; Stephanie Letast; Yassir K Mahdi; Marie-Lise Jourdan; Sandrine Dallet-Choisy; Sylvain Marchand-Adam; Christine Kellenberger; Marie-Claude Viaud-Massuard; Dieter E Jenne; Francis Gauthier
Journal:  Semin Immunopathol       Date:  2013-02-06       Impact factor: 9.623

7.  Catalytic activity and inhibition of wegener antigen proteinase 3 on the cell surface of human polymorphonuclear neutrophils.

Authors:  Brice Korkmaz; Jérôme Jaillet; Marie-Lise Jourdan; Alexandre Gauthier; Francis Gauthier; Sylvie Attucci
Journal:  J Biol Chem       Date:  2009-05-15       Impact factor: 5.157

8.  Proteinase 3 and prognosis of patients with acute myocardial infarction.

Authors:  Leong L Ng; Sohail Q Khan; Hafid Narayan; Paulene Quinn; Iain B Squire; Joan E Davies
Journal:  Clin Sci (Lond)       Date:  2011-03       Impact factor: 6.124

Review 9.  ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients.

Authors:  Divi Cornec; Emilie Cornec-Le Gall; Fernando C Fervenza; Ulrich Specks
Journal:  Nat Rev Rheumatol       Date:  2016-07-28       Impact factor: 20.543

10.  Selective killing of B-cell hybridomas targeting proteinase 3, Wegener's autoantigen.

Authors:  Katrin S Reiners; Hinrich P Hansen; Anne Krüssmann; Gisela Schön; Elena Csernok; Wolfgang L Gross; Andreas Engert; Elke Pogge Von Strandmann
Journal:  Immunology       Date:  2004-06       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.